Auris Health raises another $220M to commercialize its robotic surgery platform

Formerly known as Auris Surgical Robotics, the Fierce 15 winner received FDA approval in lung cancer patients in March. (Auris Health)

Robotic surgery platform developer Auris Health has raked in another $220 million in equity financing, bringing its fundraising total to more than $700 million.

The new money will be used to help the 2016 Fierce 15 winner transition to a commercial-stage company following the FDA approval of its Monarch endoscopic platform this past spring, as well as to fund the development of new robotic interventions.

“We are pleased with our progress in launching the Monarch platform, which was initiated earlier this year,” said Auris founder and CEO Frederic Moll, M.D., who previously co-founded Intuitive Surgical.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: FierceMedicalDevices' 2016 Fierce 15 | Auris Surgical Robotics

“This funding will enable us to expand our commercialization efforts for endobronchial applications, and will also support our mission to pioneer the next era of medical intervention across a broader spectrum of procedures,” Moll said.

The round was led by Partner Fund Management with participation from the company’s previous investors Mithril Capital, Lux Capital and Viking Global Investors. Wellington Management, D1 Capital Partners and Senator Investment Group also joined as new backers.

RELATED: 2018 could see a robotic surgery shake-up

Formerly known as Auris Surgical Robotics, the Redwood City, California-based company received FDA approval for diagnostic and therapeutic bronchoscopic procedures in lung cancer patients, using a flexible robotic endoscope to treat small and hard-to-reach nodules in the periphery of the lung.

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.